National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
2,051 of 2,487 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
3,257 total, page 48 of 66
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00083122
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00084604
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
NCT00085150
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer
NCT00084981
Diindolylmethane in Preventing Cancer in Healthy Volunteers
NCT00784394
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
NCT00070122
Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck
NCT00081211
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
NCT00084487
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
NCT00082888
Molecular Staging of Endometrial Cancer
NCT00340808
Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma
NCT00339898
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer
NCT00079625
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
NCT00076180
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
NCT00079404
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00084877
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00082966
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
NCT00083226
Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
NCT00083109
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00290472
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
NCT00082810
Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas
NCT00075894
Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers
NCT02090933
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
NCT00080353
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
NCT00082784
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
NCT00089180
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
NCT00068380
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
NCT00082914
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
NCT00084617
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT00084461
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
NCT00082875
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00080847
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
NCT00077922
Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II
NCT00099112
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
NCT00079235
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
NCT00077454
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00079378
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
NCT00080990
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
NCT00079274
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00079456
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
NCT00071994
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
NCT00076752
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
NCT00026754
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
NCT00965276
Genetics of Familial Testicular Cancer
NCT00342537
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
NCT00074490
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00079144
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00079170
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00078962
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
NCT00079339
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
NCT00077545
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Cancer Institute (NCI): open-pipeline peers nationwide
Peers matched on 3,257 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Cancer Institute (NCI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3,257 trials (± recruiting share)
- Mayo Clinic · 2,844 trials · 19% recruiting
- M.D. Anderson Cancer Center · 2,692 trials · 20% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Abiomed · 10% recruiting · 20 trials
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
Related
What to do with this National Cancer Institute (NCI) page
3,257 registered trials is a research-attention snapshot, not an endorsement of National Cancer Institute (NCI) or any single study.
- 326 of National Cancer Institute (NCI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Malignant Solid Neoplasm is the condition National Cancer Institute (NCI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignant Solid Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Cancer Institute (NCI) pipeline card: 3,257 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.